carolina complete health

Pharmacy Prior Approval Request for Mavyret: Initial PA Form

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: ____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext. ____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: __84__

11. Length of Therapy (in days): ☒ 8 Weeks **(Only 8 weeks can be approved with this form. Must use continuation form to request additional weeks of therapy.)**

Clinical Information

Total Length of Therapy (Check ONE):

☐ **8 weeks** = All genotypes: without cirrhosis

☐ **12 weeks =** Treatment naïve patients with a Liver or Kidney transplant recipients, or treatment-experienced patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A PI_2 without prior treatment with an NS5A inhibitor

☐ **16 weeks** = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor or a recipient with an HCV Genotype 3 and previously treated with a regiment containing PRS_3

1. Is the beneficiary 12 years of age or older or weighing at least 45kg with a diagnosis of chronic hepatitis C (CHC) with Confirmed genotype 1,2,3,4,5, or 6? ☐ **Yes** ☐ **No Genotype is:** _____ **Fibrosis stage is:** _____
2. Does the beneficiary have cirrhosis? ☐ **Yes** ☐ **No Child-Pugh is:** _____
3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? ☐ **Yes** ☐ **No** ****Lab test results MUST be attached to the PA to be approved.****
4. Which of the following are included with the submitted medical records to document the staging of liver disease:
   ☐ Metavir scores ☐ FibroSURE score ☐ IASL scores
   ☐ Batts-Ludwig scores ☐ Fibroscan score ☐ Ishak scores
   ☐ APRI score Radiological imaging consistent with cirrhosis
   ☐ Physical findings or clinical evidence consistent with cirrhosis as attested by the prescribing physician
5. Does the beneficiary have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? ☐ **Yes** ☐ **No HCV RNA (IU/ml):** _____ and/or **log10 value:** _____
6. As the provider, are you reasonably certain that treatment will improve the beneficiary's overall health status?
   ☐ **Yes** ☐**No**
7. Does the Beneficiary have an FDA labeled contraindications to Mavyret? ☐ **Yes** ☐**No**
8. Is Mavyret being used in combination with atazanavir and rifampin? ☐ **Yes** ☐**No**
9. Does the Beneficiary have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ **Yes** ☐**No**

Signature of Prescriber:_____Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to: (866)-399-0929 Pharmacy PA Call Center: (833) 585-4309